Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Reexamination Certificate
2008-01-01
2008-01-01
Kam, Chih-Min (Department: 1656)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
C424S190100, C424S242100, C435S069300, C435S252300, C435S253300, C435S320100, C530S350000, C536S023700
Reexamination Certificate
active
07314625
ABSTRACT:
The invention provides chimeric proteins comprising a non-toxicPseudomonasexotoxin A sequence and a Type IV pilin loop sequence, wherein the Type IV loop sequence is inserted within the non-toxicPseudomonasexotoxin A. The invention also provides polynucleotides encoding the chimeric proteins, and compositions comprising the polynucleotides or the chimeric proteins. The invention also provides methods for using the chimeric proteins, polynucleotides and compositions of the invention.
REFERENCES:
patent: 4892827 (1990-01-01), Pastan et al.
patent: 5082927 (1992-01-01), Pastan et al.
patent: 5328984 (1994-07-01), Pastan et al.
patent: 5458878 (1995-10-01), Pastan et al.
patent: 5512658 (1996-04-01), Pastan et al.
patent: 5573916 (1996-11-01), Cheronis et al.
patent: 5602095 (1997-02-01), Pastan et al.
patent: 5696237 (1997-12-01), Fitzgerald et al.
patent: 5705156 (1998-01-01), Pastan et al.
patent: 5705163 (1998-01-01), Pastan et al.
patent: 5854044 (1998-12-01), Pastan et al.
patent: 5863745 (1999-01-01), Fitzgerald et al.
patent: 5965406 (1999-10-01), Murphy
patent: 5980895 (1999-11-01), Pastan et al.
patent: 6011002 (2000-01-01), Pastan et al.
patent: 6022950 (2000-02-01), Murphy
patent: 6074644 (2000-06-01), Pastan et al.
patent: 6086900 (2000-07-01), Draper
patent: 6426075 (2002-07-01), Fitzgerald et al.
patent: 6498233 (2002-12-01), Wels et al.
patent: 0 439 954 (1991-08-01), None
patent: WO90/13563 (1990-11-01), None
patent: WO93/11791 (1993-06-01), None
patent: WO95/31483 (1995-11-01), None
patent: WO97/13529 (1997-04-01), None
patent: WO98/20135 (1998-05-01), None
patent: WO99/02712 (1999-01-01), None
patent: WO99/57142 (1999-11-01), None
Fitzgerald, D. et al., “Characterization of V3 Loop-Pseudomonas Exotoxin Chimeras” J. Biol. Chem. 273(16):9951-9958 (1998).
Hahn, H. et al., “Pilin-Based Anti-Pseudomonas Vaccines: Latest Developments and Perspectives” Behring Institute: Mitteilungen, Marburg, DE 98:315-325 (1997).
Hertle, R. et al., “Dual-Function Vaccine forPseudomonas aeruginosa: Characterization of Chimeric Exotoxin A-Pilin Protein” Infection and Immunity 69(11):6962-6969 (2001).
Lukac, M. et al., “Toxoid ofPseudomonas aeruginosaExotoxin A Generated by Deletion of an Active-Site Residue” Infection and Immunity 56(12):3095-3098 (1988).
Wall, D. and Kaiser, D., “ Type IV Pili and Cell Motility” Mol. Microbiol. 32(1):1-10 (1999).
U.S. Appl. No. 09/462,682, filed Apr. 28, 2000, Fitzgerald et al.
U.S. Appl. No. 10/110,880, filed Apr. 16, 2002, Fitzgerald et al.
U.S. Appl. No. 10/659,036, filed Sep. 9, 2003, Fitzgerald et al.
Ashorn, P. et al., “Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors” PNAS USA 87:8889-8893 (1990).
Benhar, I. et al., “PseudomonasExotoxin A Mutants: Replacement of surface-exposed residues in domain III with cysteine residues that can be modified with polyethylene glycol in a site-specific manner” J. Biol. Chem. 269(18):13398-13404 (1994).
Berger, E. et al., “CD4-Pseudomonas exotoxin hybrid protein blocks the spread of human immunodeficiency virus infection in vitro and is active against cells expressing the envelope glycoproteins from diverse primate immunodeficiency retroviruses” PNAS USA 86:9539-9543 (1989).
Brinkmann, U. et al., “Alteration of a protease-sensitive region ofPseudomonasexotoxin prolongs its survival in the circulation of mice” PNAS USA 89:3065-3069 (1992).
Brinkmann, U. et al., “Independent domain folding ofPseudomonasexotoxin and single-chain immunotoxins: Influence of interdomain connections” PNAS USA 89:3075-3079 (1992).
Brinkmann, U. et al., “Immunotoxins against cancer” Biochimica et Biophysica Acta 1198:27-45 (1994).
Chaudhary, V. et al., “Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein” Nature 335:369-372 (1988).
Chaudhary, V. et al., “Pseudomonasexotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity” PNAS USA 87:308-312 (1990).
Chaudhary, V. et al., “Mutagenesis ofPseudomonasexotoxin in identification of sequences responsible for the animal toxicity” J. Biol. Chem. 265(27):16303-16310 (1990).
Choe, M. et al., “B3(Fab)-PE38M: A recombinant immunotoxin in which a mutant form ofPseudomonasexotoxin is fused to the Fab fragment of monoclonal antibody B3” Cancer Res. 54:3460-3467 (1994).
Cryz, Jr., S. et al., “Safety and immunogenicity of aPseudomonas aeruginosaO-polysaccharide toxin A conjugate vaccine in humans” J. Clin. Invest. 80:51-56 (1987).
Cryz, Jr., S. et al., “Safety and immunogenicity ofEscherichia coliO18 O-specific polysaccharide (O-PS)-toxin A and O-PS-cholera toxin conjugate vaccines in humans” J. Infect. Dis. 163:1040-1045 (1991).
Cryz, Jr., S. et al., “Human immunodeficiency virus-1 principal neutralizing domain peptide-toxin A conjugate vaccine” Vaccine 13(1):67-71 (1995).
Fattom, A. et al., “Comparative immunogenicity of conjugates composed of theStaphylococcus aureustype 8 capsular polysaccharide bound to carrier proteins by adipic acid dihydrazide or N-Succinimidyl-3-(2-pridyldithio)propionate” Infection and Immunity 60(2):584-589 (1992).
Fattom, A. et al., “Laboratory and clinical evaluation of conjugate vaccines composed ofStaphylococcus aureustype 5 and type 8 capsular polysaccharides bound toPseudomonas aeruginosarecombinant exoprotein A” Infection and Immunity 61(3):1023-1032 (1993).
Jinno, Y. et al., “Domain II mutants ofPseudomonasexotoxin deficient in translocation” J. Biol. Chem. 264(27):15953-15959 (1989).
Johnson, K. et al., “Nucleotide sequence and transcriptional initiation site of twoPseudomonas aeruginosapilin genes” J. Biol. Chem. 261(33):15703-15708 (1986).
Kasturi, S. et al., “Alanine scanning mutagenesis identifies surface amino acids on domain III ofPseudomonasexotoxin required for cytotoxicity, proper folding, and secretion into periplasm” J. Biol. Chem. 267(32):23427-23433 (1992).
Kondo, T. et al., “Activity of immunotoxins constructed with modifiedPseudomonaexotoxin A lacking the cell recognition domain” J. Biol. Chem. 263(19):9470-9475 (1988).
Kreitman, R. et al., “Properties of chimeric toxins with two recognition domains: Interleukin 6 and transforming growth factor β at different locations inPseudomonasexotoxin” Biocon. Chem 3:63-68 (1992).
Kuan, C. et al., “Pseudomonasexotoxin A mutants: Replacement of surface exposed residues in domain II with cysteine residues that can be modified with polyethylene glycol in a site-specific manner” J. Biol. Chem. 269(10):7610-7616 (1994).
Kuan, C. et al., “Improved antitumor activity of a recombinant anit-Lewisγimmunotoxin not requiring proteolytic activation” PNAS USA 93:974-978 (1996).
Mansfield, E. et al., “Characterization of RFB4-Pseudomonas exotoxin A Immunotoxins targeted to CD22 on B-cell malignancies” Bioconj. Chem. 7:557-563 (1996).
Ogata, M. et al., “Processing ofPseudomonasexotoxin by a cellular protease results in the generation of a 37,000-da toxin fragment that is translocated to the cytosol” J. Biol. Chem> 265(33):20678-20685 (1990).
Ogata, M. et al., “Cell-mediated cleavage ofPseudomonasexotoxin between Arg179and Gly280generates the enzymatically active fragment which translocates to the cytosol” J. Biol. Chem. 267(35):25396-25401 (1992).
Pastan, I. et al., “Pseudomonasexotoxin: chimeric toxins” J. Biol. Chem. 264(26):15157-15160 (1989).
Que, J. et al., “Effect of carrier selection on immunogenicity of protein conjugate vaccines against Plasmodium falciparum circumsporozoites” Infect. and Immun. 56(10):2645-2649 (1988).
Reiter, Y. et al., “Engineering
Kam Chih-Min
The United States as represented by the Secretary of the Departm
Townsend and Townsend / and Crew LLP
LandOfFree
Chimeric protein comprising non-toxic Pseudomonas exotoxin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric protein comprising non-toxic Pseudomonas exotoxin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric protein comprising non-toxic Pseudomonas exotoxin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2788756